Bioanalytics
Global bioanalytical and biomarker partner supporting all phases of your drug development.
Providing vast bioanalytics expertise for innovative medicines and next-generation biologics, as well as cell and gene therapy.
Resolian’s global Bioanalytics division has an extensive track record across therapeutic modalities and biological matrices, including conventional small molecules, peptides, biologics, antibody drug conjugates (ADCs), and oligonucleotides.
Reach out to us directly to learn more about Resolian’s bioanalytical services.
Our Bioanalytical Services
Flow Cytometry
Offering a range of assays to support drug development, from pre-clinical to late-phase.
Immunoassay
Ligand binding assays developed, validated, and implemented to GxP across wide-ranging therapeutic modalities.
High Resolution Mass Spectrometry (HR-MS)
Offering experience with state-of-the-art HR-MS technology.
Bioanalytical Services Therapeutics and Testing
Oligonucleotide and Proteins
Global bioanalytical support for oligonucleotide therapeutic drug development.
Immunogenicity
Developing, validating and implementing anti-drug antibody (ADA) immunogenicity and neutralizing antibody (nAb) assays.
Peptide Analysis
Experts in offering you bioanalytical solutions using LC-MS/MS technology.
Cell and Gene Therapy
Comprehensive, purpose-built CGT services (including PCR, Flow Cytometry, ELISpot, ADA/nAb, and Biomarkers) to support your research.
Drug Conjugate Modalities
Global bioanalytical support for conjugates: ADC, PDC, AOC, and more.
Bioanalysis of Cannabinoids
An LC-MS team specializing in tailored assays for precise cannabinoid PK measurements.
Clinical Drug-Drug Interaction (DDI) Studies
Supporting in vivo DDI studies in clinical drug development through quantitative LC-MS/MS assays.
Drug Metabolism and Pharmacokinetics
Supporting early drug discovery and late-stage drug development with state-of-the-art technologies.
